Monoclonal antibodies emerge as a new treatment option for patients with multiple myeloma, significantly broadening our therapeutic landscape in this disease. CD38 is a valuable target in the treatment of multiple myeloma since this antigen is overexpressed on malignant plasma cells. 1, 2 Recently, the monoclonal CD38 antibody daratumumab has been licensed for the treatment of patients resistant to both proteasome inhibitors and immunmodulatory drugs. This antibody shows considerable efficacy even in the monotherapy setting of heavily pretreated patients with an overall response rate of about 30% as well as in combination with bortezomib and lenalidomide. [3] [4] [5] As we are entering a new era of antibody targeting in myeloma, a few considerations on practical patient management have been raised and deserve our attention, such as blood transfusions during CD38-directed treatment and correct determination of complete remission in the presence of therapeutic antibody concentrations in plasma.
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Here, we present in-vitro and in-vivo data illustrating that interference of daratumumab with diagnostic CD38 antibodies in flow cytometry represents another practical issue relevant for the management of patients with multiple myeloma who have received CD38-directed treatment.
We report on a 55-year-old patient with 17p-deleted, International Staging System (ISS) stage II multiple myeloma and almost complete bone marrow infiltration, treated at our institution with high-dose melphalan and autologous stem cell support followed by allogeneic transplant ( Figure 1A ). In the course, this patient relapsed and received a total of eight daratumumab infusions until clinical progression. Six weeks after the last daratumumab dose, we drained a new pleural effusion. Flow cytometry showed 58% of cells with positivity for CD138 and CD56. CD38 was negative on these cells with standard diagnostic CD38 antibodies and CD45 was fully expressed, contrasting substantially with this patient's CD45-/CD38+ myeloma immunophenotype at diagnosis and at first relapse after allogenic transplant ( Figure 1B ). Yet, cytology and clinical history of daratumumab treatment allowed us to correctly diagnose myelomatous pleural effusion in this progressive patient.
Although our patient had discontinued daratumumab six weeks prior to flow cytometry analysis, we suspected that the lack of CD38 detection was due to competition of the CD38 detection antibody with daratumumab. CD38 loss as mechanism of resistance in this daratumumab-refractory patient appeared unlikely since CD38 was equally undetectable on immune cells within the pleural effusion ( Figure 1B ). To discriminate potential CD38 antigen/epitope loss from antibody competition, we stained these cells with a CD38 multi-epitope antibody from Cytognos reported to bind independently of daratumumab 10 and with a noncrossreactive CD38 nanobody JK36. These stainings clearly showed preserved CD38 antigen expression on the malignant plasma cells ( Figure 1C ), confirmed by
Western blot analysis ( Figure 1D ). CD38 next-generation sequencing did not reveal any evidence of point mutations or splice variants leading to epitope loss that could explain antibody resistance and failed CD38 detection on these cells. Since the myeloma cells showed full saturation of CD38 with antibody despite daratumumab resistance, we investigated the expression of complement regulators CD55 and CD59 that impair complement-dependent cytotoxicity of daratumumab.
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Especially CD55 was highly expressed on the myeloma cells, potentially accounting for clinical resistance in this case ( Figure 1E ).
The finding of CD38 saturation by daratumumab six weeks after termination of daratumumab treatment was rather unexpected given this patient's progressive disease with high cell turnover since the last antibody infusion. Since parallel receptor-saturation studies were not performed in the context of previous daratumumab trials [3] [4] [5] , only estimates from a kinetic model, but no in-vivo target saturation data were available. According to this model, daratumumab plasma concentrations of 236 µg/ml are necessary to achieve 99% CD38 saturation invivo. [13] [14] [15] Performing the cell line saturation assay with dilutions of patient plasma, we determined a daratumumab concentration of 11.5 µg/ml in our patient six weeks after the last infusion, when preexisting and newly generated myeloma cells showed full CD38 saturation with antibody. This concentration was expected based on pharmacokinetic data from the clinical trials (peak levels, half-life, target-mediated
, but clearly challenged the target saturation model. In line with this, we found that daratumumab completely saturates cell surfaces of CD38 high and CD38 low myeloma cell lines at minimal concentrations of only 0.2 to 0.8 µg/ml (exemplarily shown in Figure 2A ). Interestingly, after thorough washing of daratumumab-treated KMS-12-BM cells and subsequent cell line expansion, loss of CD38 antibody saturation corresponded approximately to the rate of cell division, indicating that daratumumab stably persists on the membrane with only little turnover by internalization of antibody-bound CD38 ( Figure 2B ). Therefore, typical daratumumab peak plasma levels of 915 µg/ml after initial weekly dosing can be expected to oversaturate body CD38 for several months after antibody discontinuation. according to our data due to generally lower mean fluorescence intensities and partial cross-reactivity with daratumumab ( Figure 1C ).
In addition, our data may indicate inaccuracy of the published target saturation model with potential implications for rational daratumumab dosing schedules. The 16mg/kg dosing has shown superior outcomes and is certainly advisable due to relevant target-mediated clearance in patients with high tumor load at treatment initiation. 4 However, in-vivo target saturation studies should be incorporated into future clinical trials to determine if -after initial loading -longer antibody dosing intervals (e.g.
eight to 12 weeks as in CD20 targeting) may be sufficient to reach sustained CD38 saturation.
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